Bora Pharmaceuticals Co., Ltd. (BORAY)
| Market Cap | 1.66B -24.0% |
| Revenue (ttm) | 605.51M +9.1% |
| Net Income | 94.94M -22.6% |
| EPS | 0.50 -42.1% |
| Shares Out | n/a |
| PE Ratio | 17.44 |
| Forward PE | 12.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,200 |
| Average Volume | 1,063 |
| Open | 2.900 |
| Previous Close | 2.900 |
| Day's Range | 2.810 - 2.900 |
| 52-Week Range | 2.800 - 5.000 |
| Beta | 0.57 |
| RSI | 27.93 |
| Earnings Date | May 12, 2026 |
About Bora Pharmaceuticals
Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibioti... [Read more]
Financial Performance
In 2025, Bora Pharmaceuticals's revenue was 19.01 billion, an increase of 9.11% compared to the previous year's 17.43 billion. Earnings were 2.98 billion, a decrease of -22.61%.
Financial numbers in TWD Financial StatementsNews
Bora Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum
FY2025 saw record revenues, major CDMO contract wins, and expansion into biologics, with specialty pharma now 45% of sales. Investments in U.S. and Taiwan facilities, AI, and ESG initiatives position the company for strong growth in CDMO, biologics, and rare disease markets in 2026.
Bora Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant expansion and operational improvements drove 2025 revenue to $634 million, with a 700% market cap increase since 2017. Strategic U.S. investments, a focus on high-value generics and rare diseases, and strong ESG performance position the company for continued growth.
Bora Pharmaceuticals Earnings Call Transcript: Q3 2025
Record CDMO and specialty pharma growth drove a 15% year-over-year revenue increase and improved margins, despite ongoing integration and external headwinds. Strategic acquisitions, capacity expansions, and a focus on high-value products position the business for continued growth into 2026.
Bora Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 saw 9% sequential and 28% year-over-year revenue growth, with margin recovery expected in H2 as operational delays resolve. CDMO and specialty pharma segments drove strong performance, while proactive tariff and FX management minimized risks.
Bora Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 saw record CDMO growth and a strategic shift to high-margin products, despite lower total revenue due to discontinued low-margin lines and the Clinton facility closure. Gross margin rose to 42%, and specialty pharma sales surged, with strong outlook for CDMO expansion.
Bora Pharmaceuticals Earnings Call Transcript: Q4 2024
Revenues grew 35.5% and net income rose 31.5% year-over-year, driven by strong CDMO and commercial performance, strategic U.S. acquisitions, and a focus on high-margin products. 2025 outlook is positive with new capacity, product launches, and continued margin improvement.
Bora Pharmaceuticals Transcript: Bora Pharmaceuticals Co., LTD. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025
Achieved rapid revenue and profit growth, expanded global manufacturing, and executed major acquisitions in North America. Focused on integrating new assets, launching innovative CNS products, and investing in capacity, technology, and M&A for continued growth.